Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2024 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in development for the...
September 03, 2024 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive...
August 23, 2024 11:42 ET | Source: Eyenovia, Inc.

Eyenovia Announces Closing of Public Offering

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of...
August 21, 2024 09:29 ET | Source: Eyenovia, Inc.

Eyenovia Announces Pricing of $5.14 Million Public Offering

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000...
August 20, 2024 17:09 ET | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Proposed Public Offering

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell...
August 13, 2024 07:00 ET | Source: Eyenovia, Inc.

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)...
August 12, 2024 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as...
August 08, 2024 07:00 ET | Source: Eyenovia, Inc.

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today...
August 07, 2024 17:11 ET | Source: Eyenovia, Inc.

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive...
July 30, 2024 08:00 ET | Source: Eyenovia, Inc.

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right